The latest Dupixent lawsuit update, litigation status, and legal developments related to Dupixent and cutaneous T-cell lymphoma (CTCL). This hub is updated to reflect current Dupixent lawsuit news.
Last updated: March 15, 2026
No MDL yet
—
Filing stage
Check back for updates
Dupixent lawsuit news is developing as individuals who used Dupixent and were diagnosed with cutaneous T-cell lymphoma (CTCL) explore legal options. Plaintiffs allege that the manufacturer did not adequately warn about the risk of CTCL and other T-cell lymphomas.
Dupixent and cutaneous T-cell lymphoma litigation is in early stages. No federal multidistrict litigation (MDL) has been established yet. Individual cases may be filed in state or federal court. As more cases are filed, consolidation may be considered. Check this hub for updates on MDL status, key dates, and settlement developments.
If you used Dupixent and were diagnosed with cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma, you may be eligible for a free case review. Get the full picture on eligibility and how to get connected with a law firm.
Dupixent & CTCL Lawsuit – Free Case ReviewFree, confidential case review. No obligation. We may connect you with an independent law firm if appropriate.
Start Free Case ReviewThis Dupixent lawsuit news page is for informational purposes only and does not constitute legal advice. Top Tier Legal LLC is not a law firm. Litigation status may change. For the most current Dupixent lawsuit update and to see if you qualify for a free case review, visit our Dupixent & CTCL lawsuit page or contact us.